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patients usage; 3) Analyze adherence pattern at country level, based on medication 
consumption; and 4) Estimate the impact of adherence in the treatment costs. 
RESULTS: Medication for MS was responsible by 12.9% of high cost medication 
supplied by Public Sector in Brazil. During the period of analysis an average of 34.4% 
of patients adhere to treatment from 10 to 12 months. Patients treated were distributed
among therapeutics alternative as follow: 60.66% to interferon-1a (two brands), 
20.5% to interferon-1b and 18.85 to glatiramer acetate. It was possible to detect an
increase in drugs association. We found the following adherence per treatment: 36.9%
to glatiramer acetate, 33.67% to interferon-1a (two brands) and 32.3% to interferon-
1b. Due to these levels of adherence the annual costs per patient treated was USD
27,824 to glatiramer acetate, US$42,151 to interferon-1a (two brands) and US$34,038 
to interferon-1b. Total treatment costs was higher than USD92 millions per year
(R$2.5 / USD1.0), the distribution of costs begins to diverge from patients distribution 
due to combination therapy. CONCLUSIONS: National guidelines standardize care, 
but the analysis of treatment patterns points to low treatment adherence. Due to actual 
levels of adherence the costs per patient treated was three times higher than the 
expected. Actions taken to change these levels will have a considerable impact to 
reduce the cost per patient treated.
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OBJECTIVES: The objective of the study was to characterize variance in the utilization 
of immunosuppressant agents among kidney transplant patients across academic 
medical centers (AMC), and to illustrate potential differences in clinical and economic
outcome measures. METHODS: A retrospective database analysis, representing 
48 AMCs participating in the University HealthSystem Consortium’s (UHC) Clinical 
Resource Manager (CRM), was conducted on inpatients discharged between July
2007 and June 2008. Administrative data examined included total discharges for 
kidney transplants, source of renal allograft, cases with complications, immunosup-
pressant utilization, length of therapy (LOT), length of stay (LOS), days in intensive 
care unit (ICU), in-hospital mortality rate, estimated immunosuppressant cost, and 
estimated hospital costs. Descriptive statistics were used to evaluate data. RESULTS:
The mean LOT and number of institutions utilizing particular agents varied. Cyclo-
sporine was used in an average 16% of transplants. Tacrolimus and mycophenolate
mofetil had a mean utilization of 83% (4% to 100%) and 92% (39% to 100%) 
respectively. Sirolimus and azathioprine were administered in an average 12% (1% to
75%) and 2% (1% to 8%) respectively. Antithymocyte globulin, equine was dis-
pensed in an average 28% (1% to 91%) of cases. Antithymocyte globulin, rabbit was
used in an average 53% (1% to 100%) of cases. Basiliximab and daclizumab were 
utilized in an average 31% (1% to 96%) and 33% (1% to 89%). Thirty-three institu-
tions utilized three or more agents in greater than 50% of their kidney transplants. 
Agents that contributed most signiﬁ cantly to immunosuppressant cost were antithy-
mocyte globulin and basiliximab. The mean LOS index was 1.1 (0.6 to 1.7). The mean
days spent in the ICU was 2.8 (1.6 to 8.0) days. The mean in-hospital mortality rate 
was 0.47%. The estimated average immunosuppressant cost per case was $4249.
CONCLUSIONS: Considerable variation exists among institutional utilization of 
immunosuppressive agents, LOT, and associated medication costs per case.
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OBJECTIVES: Abnormalities in mineral metabolism (MM) are associated with 
increased morbidity and mortality in patients with chronic kidney disease (CKD). 
PhotoGraphTM software was designed to allow dialysis centres to track MM and
assess treatment efﬁ cacy. Recent studies in other patient populations have suggested 
that restricted access to drugs was associated with poorer patient outcomes in the 
Canadian health care setting. The aim of this study was to compare MM management 
among dialysis patients who live in provinces with open vs. restricted access to
expensive drugs. METHODS: A sample of 50 Canadian dialysis centres which used 
PhotoGraphTM were selected. Phosphorus (P), calcium (Ca), intact parathyroid
hormone (iPTH) and calcium-phosphate product (CaXP) were measured and com-
pared between provinces with open and restricted access. Data were analyzed by
phosphate binder type. RESULTS: MM targets were more likely to be reached by 
patients residing in provinces with formularies allowing more open access to non-
calcium based phosphate binders: P: 61.6% vs. 54.9%; Ca: 59% vs. 44.8%; iPTH:
31.1% vs. 27.3%; CaXP: 85.4% vs. 76.9%. Patients residing in provinces with more 
restrictive formularies were more likely to receive doses of calcium that exceed the
maximum recommended in treatment guidelines (i.e., 1.5 g/day) than those with 
more open listings (62% vs. 15%). In addition, patients residing in provinces with
restricted access to sevelamer were less likely to receive this drug (16.2% vs. 42%).
CONCLUSIONS: MM was better managed among patients in settings with more open 
access to non-calcium based phosphate binders. There is a reasonable expectation that 
this may translate to better outcomes and reduced mortality among hemodialysis 
patients.
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OBJECTIVES: Cardiovascular disease is the leading cause of death among patients
with chronic kidney disease (CKD). Vascular calciﬁ cation (VC) is a common feature 
of CKD that predicts mortality and may contribute to future outcomes. CKD treatment 
guidelines recommend that calcium-based phosphate binders (CBBs) be restricted to 
doses of 1.5 g/day elemental calcium, however a previous study showed that this dose 
was associated with VC in CKD. Similarly, the use of calcium (1.5 g/day) has been 
associated with poorer cardiovascular outcomes in other patient populations (e.g., 
postmenopausal women). The aim of this review was to compare the prevalence of 
VC among CKD patients treated with CBBs and sevelamer. METHODS: A literature 
search using Medline was conducted using the following terms: CBB, calcium carbon-
ate, calcium acetate, non-CBB, sevelamer, lanthanum, vascular calciﬁ cation, coronary
and aorta. Studies reporting mean changes from baseline (%) in VC scores in CBB 
and sevelamer groups were used for data extraction. RESULTS: Increased progression 
of coronary calciﬁ cation was observed in CBB groups as compared to sevelamer:
13.4% to 50.8% vs. 8.0% to 23.4% (n  6 studies). Sevelamer was associated with 
regression of aortic calciﬁ cation compared to CBBs: 71.3% to 13.4% vs. 5.7% to 
135% (n  3 studies). Average doses of calcium ranged from 1.39 to 2.3 g/day. 
CONCLUSIONS: Although the doses of elemental calcium used in these studies
approached those recommended by treatment guidelines, CBBs were associated with
increased progression of VC. CBBs are associated with increased VC, a predictor for 
mortality, even when calcium doses concur with current standards of practice. More
research on the impact of CBBs on VC and future outcomes is required.
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OBJECTIVES: Two-thirds of patients with Chronic Kidney Disease (CKD) will die of 
cardiovascular disease (CVD). In addition, 30 year old dialysis patients have a 500-
fold increased mortality risk vs. an age-matched general population. Coronary artery 
calciﬁ cation (CAC) is a major risk factor for CVD in CKD patients. Increased serum 
calcium accelerates this process, which suggests that calcium-based phosphate binders
(CBBs) may accelerate CAC and increase mortality. The aim of this systematic review
was to determine the effect of CBBs vs. non-CBBs on all-cause mortality and CAC
among patients with CKD. METHODS: We conducted a detailed search of several
electronic databases (e.g., MEDLINE, EMBASE, CINHAL) using the following terms: 
kidney disease, phosphate binders, calcium dialysis, phosphate levels, CV events and 
mortality. Standard Cochrane methods for study selection and data abstraction were
followed. We included nine studies which compared CBBs to non-CBBs. RESULTS:
Fifty-seven articles were retrieved for detailed evaluation. Sevelamer was the only
non-CBB noted in the nine trials which met the inclusion criteria. Sevelamer was 
associated with a trend towards reduction in all-cause mortality (RR 0.81; 95% CI 
0.65–1.02), p  0.07 vs. CBBs. Overall difference in change of CAC scores among 
those taking sevelamer vs. CBBs was 76.35 (95% CI 158.25 – 5.55), p  0.07. 
CONCLUSIONS: Compared to CBBs, sevelamer is associated with a non-signiﬁ cant 
trend toward reduced all-cause mortality. This is concordant with the trend toward a 
modest reduction in CAC progression with sevelamer. Since CBBs are used frequently 
in CKD patients, this systematic review highlights the need to further evaluate the 
safety of CBBs in this high-risk population.
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OBJECTIVES: This study aimed to compare the life expectancy, expected years of life 
lost (EYLL) and survival between patients under hemodialysis (HD) and peritoneal
dialysis (PD). METHODS: Adult patients who underwent maintenance dialysis at
National Taiwan University Hospital from 1995 to 2006 were followed-up until the 
